Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ac-225 Rosopatamab Tetraxetan in PSMA PET-Positive Castration-Resistant Prostate Cancer
NCT06549465Phase 2Recruiting
- Sponsor
- Convergent Therapeutics
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CONV01-α in castration-resistant prostate cancer (CRPC), sponsored by Convergent Therapeutics. Started Aug 2024; status: recruiting.
02
Drugs
CONV01-α
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06549465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549465.